RUNX1 Foundation dba RUNX1 Researc… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2016

Legal Domicile

Principal Officer

Katrin Ericson

Phone

8058804105

Tax Period

2024-01-01 to 2024-12-31

RUNX1 Foundation dba RUNX1 Research Program, founded in 2016, is a community nonprofit in the Medical Research sector that reported $2.4M in total revenue in fiscal year 2024. Revenue surged 55% from the prior year, signaling strong growth momentum.

Program Service Accomplishments

Program 1

Expenses: $1,081,014

RUNX1 Research Program: 2024 Independent grants include continued support of researchers at U Penn: Dr. Nancy Speck ($175,000) in the optimization of RUNX1-FPD CHIP mouse models, and Dr. Ximena...

RUNX1 Research Program: 2024 Independent grants include continued support of researchers at U Penn: Dr. Nancy Speck ($175,000) in the optimization of RUNX1-FPD CHIP mouse models, and Dr. Ximena Jordan-Bruno, Biobanking Lead ($60,000), as well as the support of three clinical studies at MD Anderson Cancer Center ($109,058) and Childrens Hospital of Philadelphia ($148,750) - one testing low dose sirolimus in RUNX1-FPD patients and the other two assessing the safety and feasibility of harvesting and banking blood stem cells from RUNX1-FPD patients. Other Recipients include Oregon Health & Sciences ($62,296), Univ of Mass ($46,875) and various small grants ($16,051)

Program 2

Expenses: $472,162

RUNX1-ALSF: Sponsored Research. 2024 co-funding partnership with Alexs Lemonade Stand Foundation (ALSF) continued, a wide array of ground breaking research projects spanning basic science honing in on gene regulatory networks affected by RUNX1 mutations, classification of RUNX1 variants via novel saturation mutagenesis methods, modeling clonal evolution driven by common secondary somatic mutations, development of clinical consensus guidelines for RUNX1-FPD and defining the role of NLRP3 inflammasome in RUNX1 deficiency.

Program 3

Expenses: $456,195

American Cancer Society: RRP launched a co-funding partnership with ACS to fund both team awards and individual awards to support early clinical trials and/or translational research aimed at...

American Cancer Society: RRP launched a co-funding partnership with ACS to fund both team awards and individual awards to support early clinical trials and/or translational research aimed at preventing the onset of blood cancers in RUNX1-FPD. The application deadline was in 2024 and the announcements for these 4 year grants will be made in 2025.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $2,394,842

Program Service Revenue $0

Investment Income $7,350

Other Revenue $0

TOTAL REVENUE $2,402,192

Expense Breakdown

Grants Paid $1,101,158

Salaries & Benefits $919,068

Fundraising Expenses $159,222

Program Expenses $2,009,371

Other Expenses $332,111

TOTAL EXPENSES $2,352,337

Year-over-Year Comparison

	2024	2023	Change
Revenue	$2,402,192	$1,549,012	+0.6%
Expenses	$2,352,337	$2,069,746	+0.1%
Net Income	$49,855	$-520,734	-1.1%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$450,023

Total Directors

$450,023

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Katrin Ericson	President Executive Director	55.00	Officer Director	$450,023	$0	$450,023
Amanda Eggen	Director of Patient Engagement	50.00	Highest	$147,966	$11,837	$159,803
Alex Gonzalez	Director of Development	40.00	Highest	$139,473	$6,448	$145,921
Timothy Babich	Chairperson	5.00	Officer Director	$0	$0	$0
Monica Babich	Secretary Treasurer CFO	5.00	Officer Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	No data	No data	No data	No data
2024	$2,402,192	$2,352,337	$319,651	$49,855
2023	$1,549,012	$2,069,746	$1,031,227	$-520,734
2022	$670,719	$2,880,432	$807,381	$-2,209,713
2021	$5,336,089	$2,608,769	$3,085,064	$2,727,320
2020	$1,432,405	$1,649,134	$310,712	$-216,729
2019	$2,367,314	$2,138,318	$328,583	$228,996

RUNX1 Foundation dba RUNX1 Research Program